...
首页> 外文期刊>International angiology: A journal of the International Union of Angiology >Atorvastatin therapy is associated with improvement of oxidized low-density lipoprotein cholesterol levels, which correlates with the degree of stenosis in patients with carotid atheromatosis with and without prior angioplasty.
【24h】

Atorvastatin therapy is associated with improvement of oxidized low-density lipoprotein cholesterol levels, which correlates with the degree of stenosis in patients with carotid atheromatosis with and without prior angioplasty.

机译:阿托伐他汀疗法可改善氧化型低密度脂蛋白胆固醇水平,这与有或没有先行血管成形术的颈动脉粥样硬化患者的狭窄程度有关。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: Oxidized low-density lipoprotein (oxLDL) is a pivotal factor of the atheromatous process. Statins reduce atheromatosis and cardiovascular risk. The aim of the present study was to investigate the effect of statin therapy on circulating oxLDL and the possible impact of such effect on stenosis due to carotid artery atheromatosis. METHODS: A total of 100 patients (76 males, median age 68 years) with carotid atheromatosis were enrolled. Those with stenosis >70% (n=50) were pre-treated with carotid angioplasty, whereas those with <70% were treated conservatively. Both groups were given low-dose atrorvastatin, tittered to maintain LDL cholesterol <100 mg/dL. Anthropometrics, complete lipid profile, and oxLDL were obtained in 1, 3, 6 and 12 months. Stenosis was evaluated by ultrasonography at baseline and 12 months. RESULTS: Lipid profile significantly improved at 12 months and oxLDL fell from 62.26+/-22.03 mg/dL at baseline to 44.49+/-21.75 mg/dL at 12 months (P<0.001). In the invasively pretreated group no restenosis was noticed; in the conservatively treated group a significant reduction of stenosis was demonstrated (47.6+/-13.2% vs 37.7+/-15.7%, P<0.001). The decrease of oxLDL correlated with the reduction of stenosis (r=0.17, P=0.018). In multivariate analysis, oxLDL was an independent risk factor for re-stenosis (hazard ratio=4.319, P<0.001). CONCLUSION: A marked reduction of oxLDL was shown in patients with carotid atheromatosis treated with low-dose atorvastatin. Moreover, oxLDL could be a measure of the degree of stenosis in such patients.
机译:目的:氧化的低密度脂蛋白(oxLDL)是动脉粥样硬化过程的关键因素。他汀类药物可减少动脉粥样硬化和心血管疾病的风险。本研究的目的是研究他汀类药物疗法对循环oxLDL的作用以及这种作用对由于颈动脉粥样硬化引起的狭窄的可能影响。方法:共纳入100例颈动脉粥样硬化病患者(76例男性,中位年龄68岁)。狭窄> 70%(n = 50)的患者接受颈动脉血管成形术预处理,而狭窄<70%的患者则进行保守治疗。两组均给予小剂量阿托伐他汀,滴定以维持LDL胆固醇<100 mg / dL。在1、3、6和12个月内获得了人体测量学,完整的脂质分布和oxLDL。在基线和12个月时通过超声检查评估狭窄。结果:12个月时血脂水平显着改善,oxLDL从基线时的62.26 +/- 22.03 mg / dL降至12个月时的44.49 +/- 21.75 mg / dL(P <0.001)。在侵入性预处理组中,未发现再狭窄;在保守治疗组中,狭窄显着减少(47.6 +/- 13.2%对37.7 +/- 15.7%,P <0.001)。 oxLDL的减少与狭窄的减少相关(r = 0.17,P = 0.018)。在多变量分析中,oxLDL是再狭窄的独立危险因素(危险比= 4.319,P <0.001)。结论:低剂量阿托伐他汀治疗的颈动脉粥样硬化患者的oxLDL水平明显降低。此外,oxLDL可以衡量此类患者的狭窄程度。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号